Opus Genetics Inc. (IRD)
NASDAQ: IRDHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
IRD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $366.89M
- EPS (TTM)
- -$1.28
- Dividend yield
- None
- 52-week range
- 1.70 – 7.07
- Day range
- 4.25 – 4.66
- Volume / Avg
- 1.84M / 2.35M
- Beta
- —
- Shares outstanding
- 83.20M
52-week range
IRD stock today
On Oct 7, IRD ended the session at $4.41, adding $0.03 (0.68%), versus the S&P 500's 0.22% decline. Shares are 37.6% below their 52-week high of $7.07, set on Sep 9, 2026 and 159.4% above the 52-week low of $1.70, in the middle of the past year's range. IRD is up 119.4% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 117.2%.
Opus Genetics has posted a net loss over the last twelve months (EPS of -$1.28), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Opus Genetics
Company profileOpus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. George Magrath M.B.A., M.D., M.S.
- Headquarters
- Durham, NC
- Employees
- 27
- Website
- opusgtx.com
Analyst forecast
ForecastConsensus (18 analysts)
strong_buy
Avg. price target
$13.41+204.08%
- Strong buy 3
- Buy 15
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
IRD news
All IRD newsOpus Genetics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GALTGalectin Therapeutics Inc. | 3.62 | -3.72% | $365.08M | vs IRD |
| FENCFennec Pharmaceuticals Inc. | 10.36 | +0.10% | $363.30M | vs IRD |
| ARCTArcturus Therapeutics Holdings Inc. | 12.77 | -1.81% | $362.82M | vs IRD |
| TTRXTurn Therapeutics Inc. | 12.10 | +3.95% | $367.45M | vs IRD |
| ENTAEnanta Pharmaceuticals Inc. | 12.37 | +1.64% | $360.28M | vs IRD |
| KYTXKyverna Therapeutics Inc. | 6.17 | +0.16% | $381.57M | vs IRD |
| CCCCC4 Therapeutics Inc. | 2.82 | -2.08% | $346.93M | vs IRD |
| RLMDRelmada Therapeutics Inc. | 3.25 | -0.91% | $346.68M | vs IRD |
Indexes, lists and sector
Appears in lists
Opus Genetics stock FAQ
What is Opus Genetics's stock price today?
IRD last traded at $4.41 as of Oct 7, 4:00 PM EDT, up 0.68% on the day. Prices are delayed at least 15 minutes.
Does Opus Genetics pay a dividend?
No. Opus Genetics does not currently pay a regular cash dividend.
Who is Opus Genetics's CEO?
Dr. George Magrath M.B.A., M.D., M.S. is the chief executive officer of Opus Genetics Inc., which has about 27 employees.
Has IRD ever split its stock?
Yes. The most recent IRD stock split was a 1-for-4 split on Nov 6, 2020, one of 3 splits on record.
What is the IRD 52-week high?
The 52-week high for IRD is $7.07 and the 52-week low is $1.70. The stock is currently 37.6% below its high.